DK3010910T3 - Pyrimidindionforbindelser mod hjertetilstande - Google Patents

Pyrimidindionforbindelser mod hjertetilstande Download PDF

Info

Publication number: DK3010910T3
Authority: DK; Denmark
Prior art keywords: pyrimidindion; compounds against; heart conditions; against heart; conditions
Prior art date: 2013-06-21

Application number

DK14738986.0T

Other languages

English (en)

Inventor

Johan Oslob

Robert Anderson

Danielle Aubele

Marc Evanchik

Jonathan Charles Fox

Brian Kane

Puping Lu

Robert Mcdowell

Hector Rodriguez

Yonghong Song

Arvinder Sran

Original Assignee

Myokardia Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-06-21

Filing date

2014-06-19

Publication date

2020-02-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51177189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3010910(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-06-19 Application filed by Myokardia Inc filed Critical Myokardia Inc

2020-02-17 Application granted granted Critical

2020-02-17 Publication of DK3010910T3 publication Critical patent/DK3010910T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

DK14738986.0T 2013-06-21 2014-06-19 Pyrimidindionforbindelser mod hjertetilstande DK3010910T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201361838088P	2013-06-21	2013-06-21
US201461939655P	2014-02-13	2014-02-13
US201461981366P	2014-04-18	2014-04-18
PCT/US2014/043192 WO2014205223A1 (en)	2013-06-21	2014-06-19	Pyrimidinedione compounds against cardiac conditions

Publications (1)

Publication Number	Publication Date
DK3010910T3 true DK3010910T3 (da)	2020-02-17

Family

ID=51177189

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK14738986.0T DK3010910T3 (da)	2013-06-21	2014-06-19	Pyrimidindionforbindelser mod hjertetilstande

Country Status (38)

Country	Link
US (9)	US9181200B2 (da)
EP (2)	EP3702352A1 (da)
JP (5)	JP6603213B2 (da)
KR (4)	KR102359158B1 (da)
CN (2)	CN109384729B (da)
AU (5)	AU2014281408B2 (da)
BR (1)	BR112015031864B1 (da)
CA (1)	CA2915967C (da)
CL (1)	CL2015003689A1 (da)
CR (1)	CR20160032A (da)
CY (2)	CY1122964T1 (da)
DK (1)	DK3010910T3 (da)
DO (1)	DOP2015000300A (da)
EA (2)	EA030846B1 (da)
ES (1)	ES2773250T3 (da)
FI (1)	FIC20230036I1 (da)
FR (1)	FR23C1047I2 (da)
GT (1)	GT201500348A (da)
HR (1)	HRP20200379T1 (da)
HU (2)	HUE047566T2 (da)
IL (6)	IL317628A (da)
LT (2)	LT3010910T (da)
MX (3)	MX382520B (da)
MY (1)	MY190860A (da)
NL (1)	NL301253I2 (da)
NO (1)	NO2023043I1 (da)
PE (1)	PE20160208A1 (da)
PH (2)	PH12015502794B1 (da)
PL (1)	PL3010910T3 (da)
PT (1)	PT3010910T (da)
RS (1)	RS59906B1 (da)
SG (2)	SG11201510163TA (da)
SI (1)	SI3010910T1 (da)
SM (1)	SMT202000071T1 (da)
TN (1)	TN2015000553A1 (da)
UA (1)	UA117929C2 (da)
WO (1)	WO2014205223A1 (da)
ZA (1)	ZA201508959B (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6010545B2 (ja)	2010-12-23	2016-10-19	トゥエルヴ，インコーポレイテッド	僧帽弁の修復および置換のためのシステム
CA2840084C (en)	2011-06-21	2019-11-05	Foundry Newco Xii, Inc.	Prosthetic heart valve devices and associated systems and methods
US9039757B2 (en)	2011-10-19	2015-05-26	Twelve, Inc.	Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US11202704B2 (en)	2011-10-19	2021-12-21	Twelve, Inc.	Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
AU2012325813A1 (en)	2011-10-19	2014-04-03	Twelve, Inc.	Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
CA2848334C (en)	2011-10-19	2020-10-20	Twelve, Inc.	Devices, systems and methods for heart valve replacement
US9579198B2 (en)	2012-03-01	2017-02-28	Twelve, Inc.	Hydraulic delivery systems for prosthetic heart valve devices and associated methods
WO2014205234A1 (en) *	2013-06-21	2014-12-24	MyoKardia, Inc.	Cycloalkyl-substituted pyrimidinedione compounds
SMT202000071T1 (it) *	2013-06-21	2020-03-13	Myokardia Inc	Composti di pirimidinadione contro le condizioni cardiache
US9346776B2 (en)	2014-02-13	2016-05-24	Takeda Pharmaceutical Company Limited	Fused heterocyclic compound
US9527835B2 (en)	2014-02-13	2016-12-27	Incyte Corporation	Cyclopropylamines as LSD1 inhibitors
US9428470B2 (en)	2014-02-13	2016-08-30	Takeda Pharmaceutical Company Limited	Heterocyclic compound
PH12020552066A1 (en)	2014-02-13	2022-05-11	Incyte Corp	Cyclopropylamines as lsd1 inhibitors
RS59534B1 (sr)	2014-02-13	2019-12-31	Incyte Corp	Ciklopropilamini kao lsd1 inhibitori
WO2016007722A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TWI687419B (zh)	2014-07-10	2020-03-11	美商英塞特公司	作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
EP3626720A1 (en)	2015-04-03	2020-03-25	Incyte Corporation	Heterocyclic compounds as lsd1 inhibitors
MX389824B (es)	2015-08-12	2025-03-20	Incyte Holdings Corp	Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1).
CN106432222A (zh) *	2016-09-19	2017-02-22	丹诺医药(苏州）有限公司	8‑氯‑1‑环丙基‑7‑氟‑9‑甲基‑4‑氧‑4‑氢‑喹嗪‑3‑羧酸酯及其制备方法
CN106946851B (zh) *	2017-03-14	2019-11-12	牡丹江医学院	一种用于预防和治疗肾结石的药物
US10575950B2 (en)	2017-04-18	2020-03-03	Twelve, Inc.	Hydraulic systems for delivering prosthetic heart valve devices and associated methods
US10646338B2 (en)	2017-06-02	2020-05-12	Twelve, Inc.	Delivery systems with telescoping capsules for deploying prosthetic heart valve devices and associated methods
AU2018311974B2 (en) *	2017-08-04	2024-03-07	MyoKardia, Inc.	Mavacamten for use in the treatment of hypertrophic cardiomyopathy
SMT202400329T1 (it)	2018-01-19	2024-09-16	Cytokinetics Inc	Analoghi di diidrobenzofurano e indene come inibitori di sarcomero cardiaco
JP7438148B2 (ja)	2018-06-26	2024-02-26	サイトキネティックス，インコーポレイテッド	心臓サルコメア阻害剤
JP7610985B2 (ja)	2018-06-26	2025-01-09	サイトキネティックス，インコーポレイテッド	心臓サルコメア阻害剤
US10968200B2 (en)	2018-08-31	2021-04-06	Incyte Corporation	Salts of an LSD1 inhibitor and processes for preparing the same
EP3843842A1 (en) *	2018-08-31	2021-07-07	Cytokinetics, Inc.	Cardiac sarcomere inhibitors
HUE068265T2 (hu)	2018-10-29	2024-12-28	Myokardia Inc	Tetrahidropirán(THP)-szubsztituált biciklusos pirimidindion-származékok
WO2020151605A1 (zh) *	2019-01-25	2020-07-30	青岛吉澳医药科技有限公司	氘代苯甲氨嘧啶二酮衍生物及其用途
CN110698415B (zh) *	2019-10-21	2023-05-09	上海先行医药开发有限公司	一种肌球蛋白抑制剂及其制备方法和用途
MX2022005465A (es) *	2019-11-10	2022-08-08	Myokardia Inc	Metodos de tratamiento con modulador de miosina.
HUE069154T2 (hu) *	2020-01-28	2025-02-28	Assia Chem Ind Ltd	A mavakamten szilárd állapotú formái és eljárás elõállításukra
JP2023540485A (ja)	2020-08-28	2023-09-25	マイオカーディア，インク	ミオシンモジュレーターによる治療方法
KR20230110538A (ko)	2020-11-20	2023-07-24	지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드	트라이아진 다이온 유도체, 이의 제조 방법 및 의약에서 이의 용도
CN116507621B (zh) *	2020-11-24	2025-10-17	江苏恒瑞医药股份有限公司	嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114539229B (zh) *	2020-11-24	2024-10-22	江苏恒瑞医药股份有限公司	嘧啶二酮类衍生物、其制备方法及其在医药上的应用
WO2022162701A1 (en) *	2021-02-01	2022-08-04	Dr. Reddy's Laboratories Limited	Process for preparation of mavacamten and solid state forms thereof
CA3209693A1 (en) *	2021-02-25	2022-09-01	Xiaobing Yan	Substituted pyridine-2,4-dione derivatives
WO2022187501A1 (en)	2021-03-04	2022-09-09	Cytokinetics, Inc.	Cardiac sarcomere inhibitors
CN112939876A (zh) *	2021-03-10	2021-06-11	杭州科巢生物科技有限公司	Mavacamten的晶型I及其制备方法
WO2022189599A1 (en)	2021-03-12	2022-09-15	Sandoz Ag	Crystalline forms of mavacamten for the treatment of hcm
IL305234A (en) *	2021-03-17	2023-10-01	Hansoh Bio Llc	Nitrogen-containing heterocyclic ketones, preparation methods and medical use thereof
WO2023286719A1 (ja) *	2021-07-13	2023-01-19	日本曹達株式会社	ウラシル化合物の製造方法
JP7315632B2 (ja) *	2021-09-16	2023-07-26	楽天グループ株式会社	特典付与システム、特典付与方法、及びプログラム
CN116410143A (zh) *	2021-12-29	2023-07-11	杭州奥默医药股份有限公司	一种多取代脲嘧啶衍生物及其制备方法和应用
US20250154108A1 (en) *	2022-01-27	2025-05-15	Cms Research & Development Pte. Ltd.	Crystal form of 7-azaspiro[4,5]decane-6,10-dione compound and preparation method therefor
WO2023199258A1 (en)	2022-04-13	2023-10-19	Teva Pharmaceuticals International Gmbh	Solid state forms of mavacamten and process for preparation thereof
EP4514355A1 (en)	2022-04-26	2025-03-05	MyoKardia, Inc.	Methods of administering myosin inhibitors
JP2025517714A (ja)	2022-05-20	2025-06-10	江蘇恒瑞医薬股▲ふん▼有限公司	トリアジンジオン系誘導体の結晶形及び調製方法
CN119866337A (zh) *	2022-09-16	2025-04-22	江苏豪森药业集团有限公司	一种含氮杂环酮化合物的晶型及其制备方法
WO2024182469A1 (en)	2023-02-28	2024-09-06	MyoKardia, Inc.	Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy
WO2024206339A1 (en)	2023-03-27	2024-10-03	Edgewise Therapeutics, Inc.	Quinolinone amide compounds and uses thereof
WO2024218783A1 (en) *	2023-04-17	2024-10-24	Dasha Pharmaceuticals Private Limited	Green chemistry approach for synthesis of mavacamten and its intermediate using novel methodology
IT202300016653A1 (it)	2023-08-03	2025-02-03	Olon Spa	Processo per preparare mavacamten e intermedio di processo.
WO2025046606A1 (en)	2023-08-26	2025-03-06	Micro Labs Limited	Granules of mavacamten for oral administration
WO2025096779A2 (en)	2023-11-01	2025-05-08	Bristol Myers Squibb Company	Methods of treatment with a myosin inhibitor using protein levels
WO2025130408A1 (zh) *	2023-12-20	2025-06-26	福石生物科技(合肥)有限公司	一种肌球蛋白抑制剂及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1280877B (de)	1960-11-16	1968-10-24	Robugen Gmbh	Verfahren zur Herstellung von in 1-Stellung substituierten 4-Aminouracilen
JPS61205261A (ja)	1985-03-08	1986-09-11	Sagami Chem Res Center	６―置換―５―フルオロウラシル誘導体
JPH0637479B2 (ja) *	1987-12-28	1994-05-18	三井東圧化学株式会社	新規ピリミジン誘導体、その製造法およびそれを含有する抗不整脈剤
US5008267A (en) *	1988-10-29	1991-04-16	Mitsui Toatsu Chemicals, Incorporated	Pyrimidinedione compounds, method of producing the same and antiarrythmic agents containing the same
JPH03173885A (ja)	1989-12-01	1991-07-29	Mitsui Toatsu Chem Inc	ピリミジンジオン誘導体化合物、該化合物の製造法および該化合物を含む抗不整脈剤
FR2659656B1 (fr)	1990-03-15	1994-09-09	Sanofi Sa	Derives de pyrimidinedione-2,4 et medicaments les contenant.
JPH0413669A (ja) *	1990-04-27	1992-01-17	Mitsui Toatsu Chem Inc	新規ピリミジンジオン誘導体及び該化合物を含有する抗不整脈剤
JPH06128238A (ja)	1992-10-20	1994-05-10	Mitsui Toatsu Chem Inc	新規ピリミジンジオン誘導体
EP0697407B1 (en)	1994-08-19	1997-06-25	MITSUI TOATSU CHEMICALS, Inc.	Pyrimidinedione derivatives and antiarrhythmic compositions containing same
US5516905A (en)	1994-08-30	1996-05-14	University Of Massachusetts Medical Center	Antibiotic compounds and methods to treat gram-positive bacterial and mycoplasmal infections
DK0967209T3 (da)	1998-06-26	2003-03-24	Crompton Vinyl Additives Gmbh	Hidtil ukendte NH2-modificerede 6-aminouraciler som stabilisatorer af halogenholdige polymerer
US7202051B1 (en)	1999-05-18	2007-04-10	Cytokinetics, Inc.	Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7416856B2 (en)	1999-05-18	2008-08-26	Cytokinetics, Inc.	High sensitivity assay for detection of nucleoside diphosphate production
WO2001029010A1 (en)	1999-10-21	2001-04-26	Merck & Co., Inc.	Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment
US6495337B1 (en)	2000-03-29	2002-12-17	Cytokinetics, Inc.	High throughput sarcomeric assay
WO2002102769A2 (en)	2001-06-15	2002-12-27	University Of Massachusetts	Methods for synthesizing substituted pyrimidines
US20030114414A1 (en)	2001-06-15	2003-06-19	Chengxin Zhi	Methods for synthesizing substituted pyrimidines
US20030114445A1 (en)	2001-06-15	2003-06-19	Chengxin Zhi	N3-substituted 6-anilinopyrimidines and methods to treat-Gram-positive bacterial and mycoplasmal infections
DE10208460A1 (de)	2002-02-27	2003-09-04	Bayer Ag	Uracil-Thioether
WO2004014868A2 (en) *	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
CN102127057A (zh)	2004-03-15	2011-07-20	武田药品工业株式会社	二肽基肽酶抑制剂
US20060194821A1 (en)	2005-02-18	2006-08-31	The Brigham And Women's Hospital, Inc.	Compounds inhibiting the aggregation of superoxide dismutase-1
EP2219646A4 (en) *	2007-12-21	2010-12-22	Univ Rochester	PROCESS FOR EXTENDING THE LIFE OF EUKARYOTIC ORGANISMS
GB0908193D0 (en) *	2009-05-13	2009-06-24	Albright Patents	Treatment of disease state
WO2014205234A1 (en) *	2013-06-21	2014-12-24	MyoKardia, Inc.	Cycloalkyl-substituted pyrimidinedione compounds
SMT202000071T1 (it) *	2013-06-21	2020-03-13	Myokardia Inc	Composti di pirimidinadione contro le condizioni cardiache

2014
- 2014-06-18 SM SM20200071T patent/SMT202000071T1/it unknown
- 2014-06-19 BR BR112015031864-9A patent/BR112015031864B1/pt active IP Right Grant
- 2014-06-19 PE PE2015002629A patent/PE20160208A1/es unknown
- 2014-06-19 PH PH1/2015/502794A patent/PH12015502794B1/en unknown
- 2014-06-19 EA EA201690066A patent/EA030846B1/ru unknown
- 2014-06-19 IL IL317628A patent/IL317628A/en unknown
- 2014-06-19 CN CN201811208548.XA patent/CN109384729B/zh active Active
- 2014-06-19 MX MX2015017865A patent/MX382520B/es unknown
- 2014-06-19 HR HRP20200379TT patent/HRP20200379T1/hr unknown
- 2014-06-19 KR KR1020217029573A patent/KR102359158B1/ko active Active
- 2014-06-19 IL IL310829A patent/IL310829A/en unknown
- 2014-06-19 TN TN2015000553A patent/TN2015000553A1/en unknown
- 2014-06-19 SG SG11201510163TA patent/SG11201510163TA/en unknown
- 2014-06-19 PH PH1/2021/552715A patent/PH12021552715A1/en unknown
- 2014-06-19 SG SG10201803459TA patent/SG10201803459TA/en unknown
- 2014-06-19 KR KR1020237033462A patent/KR20230144117A/ko not_active Ceased
- 2014-06-19 EP EP20155100.9A patent/EP3702352A1/en active Pending
- 2014-06-19 JP JP2016521578A patent/JP6603213B2/ja active Active
- 2014-06-19 MY MYPI2015704457A patent/MY190860A/en unknown
- 2014-06-19 LT LTEP14738986.0T patent/LT3010910T/lt unknown
- 2014-06-19 KR KR1020227003283A patent/KR20220020410A/ko not_active Ceased
- 2014-06-19 KR KR1020167001045A patent/KR102304121B1/ko active Active
- 2014-06-19 WO PCT/US2014/043192 patent/WO2014205223A1/en not_active Ceased
- 2014-06-19 EA EA201891009A patent/EA201891009A1/ru unknown
- 2014-06-19 RS RS20200149A patent/RS59906B1/sr unknown
- 2014-06-19 US US14/309,381 patent/US9181200B2/en not_active Ceased
- 2014-06-19 SI SI201431491T patent/SI3010910T1/sl unknown
- 2014-06-19 IL IL302299A patent/IL302299A/en unknown
- 2014-06-19 HU HUE14738986A patent/HUE047566T2/hu unknown
- 2014-06-19 DK DK14738986.0T patent/DK3010910T3/da active
- 2014-06-19 PT PT147389860T patent/PT3010910T/pt unknown
- 2014-06-19 AU AU2014281408A patent/AU2014281408B2/en active Active
- 2014-06-19 MX MX2021005326A patent/MX2021005326A/es unknown
- 2014-06-19 EP EP14738986.0A patent/EP3010910B1/en active Active
- 2014-06-19 PL PL14738986T patent/PL3010910T3/pl unknown
- 2014-06-19 UA UAA201600450A patent/UA117929C2/uk unknown
- 2014-06-19 ES ES14738986T patent/ES2773250T3/es active Active
- 2014-06-19 CN CN201480046057.3A patent/CN105473576B/zh active Active
- 2014-06-19 CA CA2915967A patent/CA2915967C/en active Active
2015
- 2015-10-14 US US14/883,152 patent/US9585883B2/en active Active
- 2015-12-08 ZA ZA2015/08959A patent/ZA201508959B/en unknown
- 2015-12-14 DO DO2015000300A patent/DOP2015000300A/es unknown
- 2015-12-17 GT GT201500348A patent/GT201500348A/es unknown
- 2015-12-17 IL IL243222A patent/IL243222B/en active IP Right Grant
- 2015-12-18 MX MX2022014414A patent/MX2022014414A/es unknown
- 2015-12-21 CL CL2015003689A patent/CL2015003689A1/es unknown
2016
- 2016-01-15 CR CR20160032A patent/CR20160032A/es unknown
2017
- 2017-01-18 US US15/409,369 patent/US20170281626A1/en not_active Abandoned
2018
- 2018-02-15 US US15/897,549 patent/US20180311242A1/en not_active Abandoned
- 2018-11-15 AU AU2018264088A patent/AU2018264088A1/en not_active Abandoned
2019
- 2019-10-09 JP JP2019185576A patent/JP6980734B2/ja active Active
2020
- 2020-04-15 CY CY20201100354T patent/CY1122964T1/el unknown
- 2020-06-05 US US16/893,500 patent/US20200297726A1/en not_active Abandoned
- 2020-06-26 AU AU2020204271A patent/AU2020204271B2/en active Active
- 2020-07-05 IL IL275837A patent/IL275837B/en unknown
2021
- 2021-01-13 US US17/147,821 patent/US20210346379A1/en not_active Abandoned
- 2021-08-30 IL IL285971A patent/IL285971A/en unknown
- 2021-11-17 JP JP2021186772A patent/JP7376556B2/ja active Active
2022
- 2022-03-19 US US17/699,114 patent/USRE50050E1/en active Active
- 2022-04-06 AU AU2022202298A patent/AU2022202298A1/en not_active Abandoned
2023
- 2023-01-27 US US18/160,393 patent/US20230165860A1/en not_active Abandoned
- 2023-10-26 JP JP2023183708A patent/JP2024010108A/ja active Pending
- 2023-12-01 NO NO2023043C patent/NO2023043I1/no unknown
- 2023-12-01 FI FIC20230036C patent/FIC20230036I1/fi unknown
- 2023-12-04 FR FR23C1047C patent/FR23C1047I2/fr active Active
- 2023-12-07 LT LTPA2023535C patent/LTC3010910I2/lt unknown
- 2023-12-11 HU HUS2300042C patent/HUS2300042I1/hu unknown
- 2023-12-12 NL NL301253C patent/NL301253I2/nl unknown
- 2023-12-13 CY CY2023027C patent/CY2023027I2/el unknown
2024
- 2024-02-22 US US18/584,115 patent/US20240382486A1/en active Pending
- 2024-04-16 AU AU2024202464A patent/AU2024202464A1/en active Pending
2025
- 2025-07-31 JP JP2025128210A patent/JP2025163126A/ja active Pending

Also Published As

Publication number	Publication date
US20210346379A1 (en)	2021-11-11
JP2024010108A (ja)	2024-01-23
JP6603213B2 (ja)	2019-11-06
TN2015000553A1 (en)	2017-04-06
EP3010910A1 (en)	2016-04-27
HK1223930A1 (en)	2017-08-11
US20160030428A1 (en)	2016-02-04
IL275837B (en)	2021-09-30
JP2016522263A (ja)	2016-07-28
JP2020019809A (ja)	2020-02-06
WO2014205223A1 (en)	2014-12-24
AU2020204271A1 (en)	2020-07-16
CY1122964T1 (el)	2021-10-29
CR20160032A (es)	2016-04-01
IL243222A0 (en)	2016-02-29
US20240382486A1 (en)	2024-11-21
IL317628A (en)	2025-02-01
PT3010910T (pt)	2020-02-21
JP6980734B2 (ja)	2021-12-15
EP3702352A1 (en)	2020-09-02
LTPA2023535I1 (da)	2023-12-27
EA201690066A1 (ru)	2016-05-31
SMT202000071T1 (it)	2020-03-13
SG11201510163TA (en)	2016-01-28
LT3010910T (lt)	2020-03-10
US20170281626A1 (en)	2017-10-05
PE20160208A1 (es)	2016-05-04
FR23C1047I2 (fr)	2024-11-15
BR112015031864B1 (pt)	2022-02-15
JP2025163126A (ja)	2025-10-28
PH12015502794B1 (en)	2022-09-02
PH12015502794A1 (en)	2016-03-21
MX2015017865A (es)	2016-09-06
IL285971A (en)	2021-10-31
BR112015031864A2 (pt)	2017-07-25
PH12021552715A1 (en)	2022-05-11
KR20230144117A (ko)	2023-10-13
ZA201508959B (en)	2022-09-28
CA2915967C (en)	2021-07-20
KR102359158B1 (ko)	2022-02-08
NL301253I1 (da)	2023-12-13
CY2023027I2 (el)	2024-09-20
JP2022036966A (ja)	2022-03-08
EA030846B1 (ru)	2018-10-31
HUS2300042I1 (hu)	2024-01-28
CN109384729A (zh)	2019-02-26
SG10201803459TA (en)	2018-05-30
KR20210118470A (ko)	2021-09-30
CN109384729B (zh)	2023-06-30
UA117929C2 (uk)	2018-10-25
CY2023027I1 (el)	2024-02-16
US20230165860A1 (en)	2023-06-01
DOP2015000300A (es)	2016-03-15
MX2021005326A (es)	2022-11-17
HRP20200379T1 (hr)	2020-06-12
RS59906B1 (sr)	2020-03-31
US20200297726A1 (en)	2020-09-24
US9585883B2 (en)	2017-03-07
IL243222B (en)	2020-07-30
IL302299A (en)	2023-06-01
US20180311242A1 (en)	2018-11-01
MY190860A (en)	2022-05-12
CN105473576A (zh)	2016-04-06
ES2773250T3 (es)	2020-07-10
AU2024202464A1 (en)	2024-05-02
KR20160026997A (ko)	2016-03-09
HUE047566T2 (hu)	2020-04-28
MX382520B (es)	2025-03-13
FR23C1047I1 (fr)	2024-01-12
GT201500348A (es)	2018-12-20
KR102304121B1 (ko)	2021-09-24
SI3010910T1 (sl)	2020-04-30
CN105473576B (zh)	2018-10-30
KR20220020410A (ko)	2022-02-18
US20140378464A1 (en)	2014-12-25
NO2023043I1 (no)	2023-12-01
AU2020204271B2 (en)	2022-01-06
EA201891009A1 (ru)	2018-09-28
USRE50050E1 (en)	2024-07-23
JP7376556B2 (ja)	2023-11-08
US9181200B2 (en)	2015-11-10
FIC20230036I1 (fi)	2023-12-01
EP3010910B1 (en)	2020-02-05
AU2022202298A1 (en)	2022-04-28
AU2014281408A1 (en)	2016-01-21
IL275837A (en)	2020-08-31
MX2022014414A (es)	2022-12-07
NZ715456A (en)	2021-01-29
AU2014281408B2 (en)	2018-08-16
AU2018264088A1 (en)	2018-12-06
IL310829A (en)	2024-04-01
CA2915967A1 (en)	2014-12-24
LTC3010910I2 (da)	2025-08-25
PL3010910T3 (pl)	2020-07-27
CL2015003689A1 (es)	2016-10-14
NL301253I2 (nl)	2024-01-10

Publication	Publication Date	Title
CY2023027I1 (el)	2024-02-16	Ενωσεις πυριμιδινοδιονης εναντι καρδιακων παθησεων
LT3060041T (lt)	2021-03-25	Prostaciklino junginiai
DK2970336T3 (da)	2017-11-13	Tetrahydropyrrolothiazinforbindelser
EP2968894A4 (en)	2016-12-21	MEDICAL CONNECTOR
HUE043236T2 (hu)	2019-08-28	Hálózatkezelés
EP2968867C0 (en)	2024-08-07	CATHETER ASSEMBLY
HUE047544T2 (hu)	2020-04-28	Inszekticid hatású vegyületek
HUE045209T2 (hu)	2019-12-30	Aramchol-sók
LT3031799T (lt)	2018-06-25	Aromatinis junginys
EP2982674A4 (en)	2016-08-31	PYRIDINYLPYRAZOLOCHINOLINVERBINDUNG
DE112014004161A5 (de)	2016-05-25	Rotationsrheometer
IL240904A0 (en)	2015-10-29	Azetidinyloxyphenylpyrrolidine compounds
HRP20190133T1 (hr)	2019-03-22	Heterociklički spoj
HRP20180618T1 (hr)	2018-07-13	Spojevi fluorfenilpirazola
EP2994184C0 (en)	2023-06-07	An unravelable catheter
DK3089778T3 (da)	2019-10-07	Ballonkateter
BR112016003583A2 (pt)	2018-05-02	compostos herbicidas
DK2947066T3 (da)	2019-01-02	Phenoxyalkylaminforbindelse
EP2992915A4 (en)	2016-11-09	MEDICAL HELP
LU92277B1 (fr)	2015-03-12	Composé cosmétique
DE112013006363A5 (de)	2015-10-08	Endoskop
HRP20180722T1 (hr)	2018-06-15	Spoj benzotiofena
ITMI20130606A1 (it)	2014-10-13	Composti naftoeterodiazolici disostituiti
DE112014002244A5 (de)	2016-01-21	Infusionslösung
TH1501000971A (th)	2016-09-06	สารประกอบพิแรโซโลพิริมิดีน